Janine Pilcher
Beta-agonist overuse and delay in obtaining medical review in high risk asthma: a secondary analysis of data from a randomised controlled trial
Pilcher, Janine; Patel, Mitesh; Pritchard, Alison; Thayabaran, Darmiga; Ebmeier, Stefan; Shaw, Dominick; Black, Peter; Braithwaite, Irene; Weatherall, Mark; Beasley, Richard
Authors
Mitesh Patel
Alison Pritchard
Darmiga Thayabaran
Stefan Ebmeier
Dominick Shaw
Peter Black
Irene Braithwaite
Mark Weatherall
Richard Beasley
Abstract
Asthma mortality surveys report delays in seeking medical review and overuse of beta-agonist therapy as factors contributing to a fatal outcome. However, the strength of these associations is limited because many asthma deaths are unwitnessed. We undertook a secondary analysis of data from a 24-week randomised controlled trial of 303 patients with high-risk asthma, randomised to combination budesonide/formoterol inhaler according to a single maintenance and reliever therapy regimen or fixed dose budesonide/formoterol with salbutamol as reliever (Standard) regimen. Medication use was measured by electronic monitors. The thresholds for high, marked and extreme beta-agonist use days were defined in the single maintenance and reliever therapy arm as: >8, >12 and >16 actuations of budesonide/formoterol in excess of four maintenance doses, respectively; and in the Standard arm as: >16, >24 and >32 actuations of salbutamol, respectively. Whether a medical review was obtained within 48 h of an overuse episode was determined by review of data collected during the study by participant report. The mean (standard deviation) proportion of days in which high, marked and extreme beta-agonist overuse occurred without medical review within 48 h was 0·94 (0·20), 0·94(0·15) and 0·94(0·17), and 0·92(0·19), 0·90(0·26) and 0·94(0·15) for single maintenance and reliever therapy and Standard regimens, respectively. In at least 90% of days, in which beta-agonist overuse occurred, patients did not obtain medical review within 48 h of beta-agonist overuse, regardless of the magnitude of overuse or the inhaled corticosteroid/long-acting beta-agonist regimen.
Citation
Pilcher, J., Patel, M., Pritchard, A., Thayabaran, D., Ebmeier, S., Shaw, D., …Beasley, R. (2017). Beta-agonist overuse and delay in obtaining medical review in high risk asthma: a secondary analysis of data from a randomised controlled trial. npj Primary Care Respiratory Medicine, 27(1), https://doi.org/10.1038/s41533-017-0032-z
Journal Article Type | Article |
---|---|
Acceptance Date | Mar 27, 2016 |
Online Publication Date | May 11, 2017 |
Publication Date | 2017-12 |
Deposit Date | May 30, 2017 |
Publicly Available Date | May 30, 2017 |
Journal | npj Primary Care Respiratory Medicine |
Electronic ISSN | 2055-1010 |
Publisher | Nature Publishing Group |
Peer Reviewed | Peer Reviewed |
Volume | 27 |
Issue | 1 |
DOI | https://doi.org/10.1038/s41533-017-0032-z |
Public URL | https://nottingham-repository.worktribe.com/output/860306 |
Publisher URL | https://www.nature.com/articles/s41533-017-0032-z |
Contract Date | May 30, 2017 |
Files
Pilcher 2017 Primary Care Resp Medicine.pdf
(897 Kb)
PDF
Copyright Statement
Copyright information regarding this work can be found at the following address: http://creativecommons.org/licenses/by/4.0
You might also like
Effect of smoking status on the efficacy of the SMART regimen in high risk asthma
(2016)
Journal Article
The red leg dilemma: a scoping review of the challenges of diagnosing lower limb cellulitis
(2018)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search